Research programme: alpha melanotropin - RELIEF THERAPEUTICS Holding

Drug Profile

Research programme: alpha melanotropin - RELIEF THERAPEUTICS Holding

Alternative Names: Alpha-msh - mondoBIOTECH; DasKloster 0210-01; DasKloster0210; DK 0210

Latest Information Update: 22 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator mondoBIOTECH
  • Class Melanocyte-stimulating hormones
  • Mechanism of Action T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Berylliosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Berylliosis

Most Recent Events

  • 31 Jul 2016 Preclinical development is ongoing in Beryllisis Switzerland
  • 31 Jul 2016 Alpha melanotropin is available for licensing in USA, France and United Kingdom as of July 2016.
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Berylliosis in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top